Jean-François Dufour is an expert in Hepatology at University of Bern (Switzerland). As of October 2026, ScienceLeadR ranks Jean-François Dufour in the top 1% of experts worldwide for MASH, Liver Neoplasms and Carcinoma. Jean-François Dufour has authored 442 publications, the most recent in 2026, and is an investigator in 15 clinical trials. SLR score: 1,619 (community average: 125). How the SLR is computed.

LeadR Profile

Jean-François Dufour University of Bern Switzerland
1 619 ScienceLeadR Reputation 1619
Network Map

Hepatology

Subspecialties: Gastroenterology - Oncology - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1992 - 2026

Source: PubMed

University of Bern

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 442

Citations

Citations: 41 331 1st author: 35 Last author: 117 Unique author: 18


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions.
PMID 42257496 — carcinoma, hepatocellular, incidence, liver
Liver Int20260
From hierarchy to conversion: A watermill approach to the therapeutic management of patients with hepatocellular carcinoma.
PMID 40866140 — carcinoma, hepatocellular, digestive system diseases, therapeutics
Dig Liver Dis20250
Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies.
PMID 39914746 — liver diseases, hepatitis c, income, liver, viruses, therapeutics, infections, hepatitis, virus diseases
J Hepatol Top journal202516
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.
PMID 39643944 — liver diseases, carcinoma, hepatocellular, neoplasms, immunotherapy, immune checkpoint inhibitors, liver neoplasms, therapeutics, survival rate
Hepatology202422
The Influence of Sex and Age on Survival in Patients with Hepatocellular Carcinoma.
PMID 39682209 — registries, comorbidity, carcinoma, hepatocellular, sex, diagnosis, therapeutics
Cancers (Basel)20243

Clinical Studies 15

Sources: ClinicalTrials, EU CTIS

Synthesis

Study Director: 1

By phase:

Phase 3 7
Phase 2 5
N/A 1
Phase 1 1
Phase 1/Phase 2 1

By status:

Completed 12
Active not recruiting 1
Recruiting 1
Terminated 1

By type:

Interventional 14
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 1
multicentricup10 13

Main Topics

Cohort/Consortium Investigators 11

LeadR Networks

Main global connection map